The states in India are facing a shortage of the Covid-19 vaccine, which is a serious issue. Vaccinating the people against the ongoing pandemic is the only way to root out the deadly disease.
As a big decision, the Union Government gave its nod for the Hyderabad-based Bharat Biotech to set up a Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) plant in Uttar Pradesh.
The plant will be set up in Uttar Pradesh's Bulandshahr, with an aim of manufacturing 2 crore Covaxin vaccine doses monthly reportedly.
It has to be noted that several states are facing a shortage of vaccine doses, which in turn resulted in the vaccination drive coming to a halt. A few states accused the Centre of not providing vaccine doses in required numbers.
The national capital Delhi and Maharashtra have decided to postpone the vaccination drive due to a shortage of vaccines. Delhi CM Arvind Kejriwal said that the vaccine doses will be sufficient for only a few days.
Media reports claimed that Pune-based Serum Institute and Hyderabad-based Bharat Biotech in the production plan said that by the coming August, they can manufacture nearly 10 crore and 7.8 crore vaccine doses respectively.
The vaccine doses manufactured by Bharat Biotech and Serum Institute were approved for emergency use and the two vaccines are currently being used to vaccinate people against the virus.